USFDA Conducts Pre-Market Inspection at Pashamylaram Facility of Gland Pharma
The Company is committed to address the observations and will submit its response to USFDA within the stipulated time.
Office Of Medical Device And Radiological Health | 28/08/2023 | By Manvi | 454
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy